Providence First Trust Co Purchases New Position in Gilead Sciences, Inc. $GILD

Providence First Trust Co acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 6,574 shares of the biopharmaceutical company’s stock, valued at approximately $807,000.

Several other large investors have also recently made changes to their positions in the company. Sumitomo Mitsui DS Asset Management Company Ltd grew its position in Gilead Sciences by 4.1% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 180,762 shares of the biopharmaceutical company’s stock valued at $22,187,000 after buying an additional 7,120 shares during the period. Alpha Cubed Investments LLC increased its stake in shares of Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares in the last quarter. RNC Capital Management LLC grew its holdings in Gilead Sciences by 1.6% in the fourth quarter. RNC Capital Management LLC now owns 451,991 shares of the biopharmaceutical company’s stock valued at $55,477,000 after purchasing an additional 6,947 shares during the period. Morse Asset Management Inc acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $1,215,000. Finally, Alta Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 0.9% during the 4th quarter. Alta Wealth Advisors LLC now owns 12,471 shares of the biopharmaceutical company’s stock valued at $1,531,000 after buying an additional 106 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: AHF says Gilead’s EPS could rise ~52% because state AIDS drug program shortfalls have increased reliance on commercial/retail supply, implying near-term revenue upside for Gilead’s HIV portfolio. Gilead’s Earnings Skyrocket as Florida’s AIDS Drug Program Falters, says AHF
• Positive Sentiment: Brokerage commentary and price-target coverage are constructive — a recent note cites a $157.35 target, supporting investor expectations of upside versus current levels. Brokerages Set Gilead Sciences, Inc. (NASDAQ:GILD) Price Target at $157.35
• Neutral Sentiment: Use of Yeztugo (twice-yearly HIV-prevention shot) is rising since launch, which supports Gilead’s growth story in prevention, but adoption is still early and incremental to overall revenues. Focus: Use of Gilead’s HIV prevention shot rises, but US insurance gaps remain
• Neutral Sentiment: Analyst/estimate deep dives (Zacks/market write-ups) are circulating ahead of quarterly reporting; these pieces highlight key metrics investors will watch (sales mix of HIV products, hepatitis/oncology performance, and guidance). That keeps focus on fundamentals rather than a single headline. Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
• Neutral Sentiment: Brand/marketing recognition (PLAN C Impact 50) is positive for awareness but unlikely to move near-term fundamentals materially. Eight PLAN C Client Brands Named to the 3AF 2026 Impact 50
• Negative Sentiment: Insurance coverage gaps for Yeztugo remain a real constraint — patients who want the injection can face reimbursement hurdles, which could cap upside in medium-term prevention revenue if not resolved. Use of Gilead’s HIV prevention shot rises, but US insurance gaps remain

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $118.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Tuesday, April 7th. Sanford C. Bernstein reissued an “outperform” rating and set a $160.00 target price on shares of Gilead Sciences in a research note on Wednesday, February 11th. BMO Capital Markets upped their price target on shares of Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, January 26th. Morgan Stanley lifted their price objective on Gilead Sciences from $171.00 to $175.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Finally, Barclays started coverage on Gilead Sciences in a research note on Friday, February 20th. They set an “equal weight” rating and a $155.00 price objective for the company. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $157.35.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $133.48 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $95.29 and a 52 week high of $157.29. The stock’s fifty day moving average is $140.14 and its two-hundred day moving average is $132.66. The company has a market capitalization of $165.68 billion, a P/E ratio of 19.72, a P/E/G ratio of 1.75 and a beta of 0.31. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. During the same quarter last year, the firm posted $1.90 earnings per share. Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts expect that Gilead Sciences, Inc. will post 8.62 EPS for the current year.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the sale, the chief executive officer owned 613,912 shares in the company, valued at $92,086,800. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the transaction, the insider owned 120,288 shares in the company, valued at $18,577,278.72. The trade was a 18.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 178,640 shares of company stock worth $26,584,250 over the last ninety days. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.